News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA to Meet on Long-Lasting Zyprexa
January 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Eli Lilly and Company
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
·
1 min read
·
BioSpace Insights
IN PARTNERSHIP WITH PII
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
October 16, 2025
·
1 min read
·
BioSpace Insights
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
·
2 min read
·
Tristan Manalac
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
October 15, 2025
·
2 min read
·
Annalee Armstrong
